AN2 Therapeutics (ANTX) Share-based Compensation (2021 - 2026)

AN2 Therapeutics (ANTX) has reported Share-based Compensation for 6 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation fell 28.68% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $6.7 million (down 16.41% YoY), while the FY2025 annual figure was $6.2 million, down 25.09% from the prior year.
• Share-based Compensation rose to $1.5 million in Q1 2026 per ANTX's latest filing, from $1.4 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $6.5 million in Q2 2025 and bottomed at $449000.0 in Q1 2022.
• Historically, Share-based Compensation has averaged $2.2 million across 5 years, with a median of $1.9 million in 2023.
• Annual changes were most pronounced in 2022 — Share-based Compensation soared 5512.5% — and 2026, when it retreated 28.68%.
• AN2 Therapeutics' Share-based Compensation stood at $1.5 million in 2022, then jumped by 51.63% to $2.2 million in 2023, then retreated by 20.25% to $1.8 million in 2024, then fell by 21.35% to $1.4 million in 2025, then gained by 4.29% to $1.5 million in 2026.
• Business Quant data shows ANTX's Share-based Compensation at $1.5 million in Q1 2026, $1.4 million in Q4 2025, and $5.2 million in Q3 2025.